Tracking Cathie Wood: Increased positions in Kodiak AI and genomics healthcare; reduced holdings in DraftKings and Bitcoin ETFs

On Friday, October 9, the three major US stock indices closed higher collectively. The S&P 500 rose 0.59% to 7,811.54, the Nasdaq Composite gained 0.64% to 27,366.17, and the Dow Jones Industrial Average increased 0.83% to 51,654.95, indicating an overall recovery in market risk appetite.

ARK's trading strategy for the day was quite distinct: on one hand, it increased exposure to disruptive innovation sectors such as autonomous driving, warehouse robotics, gene editing, and early cancer screening; on the other, it reduced positions in online gambling, crypto assets, and certain mature tech platforms, likely aiming to shed weaker holdings in favor of stronger ones and reallocate liquidity.

Symbols

Buy Strategy: Concentrate firepower on Embodied AI, Gene Therapy, and Precision Diagnostics

$Kodiak AI (KDK.US)$ ARK increased its holdings by another 57,540 shares. The company focuses on autonomous trucking technology, sitting at the intersection of Embodied AI and autonomous transportation. This additional investment likely reflects ARK's bullish view on the long-term potential of autonomous driving systems to reshape the cost structure of trunk-line logistics.

$Symbotic (SYM.US)$ Increased holdings by 12,592 shares. The company is transforming large-scale warehouse supply chains with AI, robotics, and automation systems, which aligns closely with ARK's Embodied AI theme.$Kodiak AI (KDK.US)$Simultaneously acquired, suggesting that ARK is increasing its bets on real-world automation from both road transport and warehouse operations ends.

ARK increased holdings$Nurix Therapeutics (NRIX.US)$ by 56,096 shares,$Kymera Therapeutics (KYMR.US)$and 2,344 shares. Both companies focus on targeted protein degradation, attempting to leverage human cellular mechanisms to clear disease-causing proteins, representing a new generation of drug R&D platforms. This may indicate that ARK is bullish on the technology's potential to break through the limitations of traditional small-molecule drugs, but the differing sizes of the position increases also show that it is still making selective allocations.

$Intellia Therapeutics (NTLA.US)$ Acquired 48,171 shares,$CRISPR Therapeutics (CRSP.US)$bought 21,487 shares,$Beam Therapeutics (BEAM.US)$and increased holdings by 19,510 shares. These three companies are developing therapies centered around CRISPR gene editing and base editing technologies, making them typical targets within ARK's Gene Therapy investment framework. The simultaneous increase in holdings on the same day may imply that ARK is not betting on a single pathway, but rather diversifying technical and clinical development risks through platform-based allocation.

$Alamar Biosciences (ALMR.US)$ Increased holdings by 31,068 shares,$Freenome (FRNM.US)$Bought 14,988 shares,$Guardant Health (GH.US)$Increased holdings by 7,210 shares.

$Alamar Biosciences (ALMR.US)$Focusing on high-sensitivity proteomics, while the latter two target blood testing, early cancer screening, and precision oncology, all pointing toward earlier disease detection and more refined biomarker analysis. This buying activity may reflect ARK's capture of the long-term opportunity as healthcare models shift from treatment to early screening and continuous monitoring.

$COMPASS Pathways (CMPS.US)$ Holdings increased by 7,700 shares. The company primarily develops psilocybin-based mental health therapies, falling within the innovative treatment sector for neuropsychiatric disorders. This increase in holdings may represent a forward-looking allocation to novel mechanisms of action and personalized psychiatric care, though related R&D and commercialization still carry significant uncertainty.

Sell-side direction: Reduce exposure to gambling and crypto, adjust holdings in mature tech stocks

$DraftKings (DKNG.US)$ Reduced holdings by 397,016 shares, marking the largest single-stock sell-off of the day. DraftKings operates an online sports betting and digital entertainment platform. Although it has digital consumer attributes, its alignment with ARK's core deep-tech themes is relatively limited. This reduction may aim to lower concentration in individual consumer internet names and free up capital for allocations in genomics and automation.

$ARK 21Shares Bitcoin ETF (ARKB.US)$ Reduced holdings by 350,270 shares,$Robinhood (HOOD.US)$Reduced holdings by 19,098 shares. The former provides exposure to Bitcoin prices, while the latter is a fintech platform covering stock and crypto asset trading. The simultaneous reduction in both may indicate that ARK is temporarily compressing exposure related to crypto and trading platforms, while managing cross-fund liquidity.

$Personalis (PSNL.US)$ Sold 160,480 shares,$CareDx (CDNA.US)$Reduced holdings by 57,911 shares.$Personalis (PSNL.US)$Focusing on cancer genome analysis and personalized tumor monitoring,$CareDx (CDNA.US)$while providing molecular diagnostics and care tools for transplant patients, all falling under the precision medicine category. Against the backdrop of ARK increasing stakes in multiple early cancer screening and gene editing companies on the same day, this round of selling is more likely to represent a rotation from weaker to stronger players within the precision medicine sector, rather than a full exit from the theme.

$SpaceX (SPCX.US)$ Reduced holdings by 22,276 shares,$Iridium Communications (IRDM.US)$Reduced holdings by 300 shares.$SpaceX (SPCX.US)$Business covers space launch and satellite communications,$Iridium Communications (IRDM.US)$and operates satellite voice and data communication networks, both belonging to space economy infrastructure. The simultaneous reduction may be a rebalancing of space and satellite communication holdings, with the latter seeing a cut of only 300 shares, which is closer to a technical fine-tuning.

$Shopify (SHOP.US)$ Reduced holdings by 12,237 shares,$Alphabet-C (GOOG.US)$Reduced holdings by 5,994 shares,$Advanced Micro Devices (AMD.US)$Sold 3,411 shares. This simultaneous reduction in more mature tech assets may aim to lower portfolio concentration and redirect capital toward early-stage innovative targets with higher elasticity.

When big players make a move, you get the intel instantly! Futubull’s [Smart Money Tracker] feature has been fully upgraded. Get instant alerts on portfolio adjustments by legendary investors, institutions, and politicians!

193K Views